PD-1抑制剂-话题@MedSci

#PD-1抑制剂#

52篇内容 | 3731人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1278926, encodeId=8b8a12e8926ae, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=JAMA Oncol：不同肿瘤和治疗方案下，PD-1抑制剂相关肺炎发生情况如何？, objectType=article, longId=77373, objectId=237ce737343, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=237ce737343, replyNumber=0, likeNumber=51, createdTime=2016-09-15, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=237ce737343, moduleTitle=JAMA Oncol：不同肿瘤和治疗方案下，PD-1抑制剂相关肺炎发生情况如何？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=237ce737343)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278925, encodeId=521112e8925a0, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存, objectType=article, longId=67206, objectId=60226e206eb, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=60226e206eb, replyNumber=0, likeNumber=111, createdTime=2016-04-28, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=60226e206eb, moduleTitle=PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=60226e206eb)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278924, encodeId=00da12e8924ad, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤, objectType=article, longId=47602, objectId=c2b04e602af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c2b04e602af, replyNumber=0, likeNumber=74, createdTime=2015-03-04, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c2b04e602af, moduleTitle=FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c2b04e602af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278923, encodeId=539d12e892344, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时, objectType=article, longId=45436, objectId=04d8454369d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=04d8454369d, replyNumber=0, likeNumber=75, createdTime=2015-01-16, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=04d8454369d, moduleTitle=Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=04d8454369d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278922, encodeId=621b12e892204, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=PD-1抑制剂对晚期鳞状非小细胞肺癌具有极其显著疗效，优于紫杉醇化疗, objectType=article, longId=45387, objectId=de7a4538e16, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=de7a4538e16, replyNumber=0, likeNumber=64, createdTime=2015-01-14, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=de7a4538e16, moduleTitle=PD-1抑制剂对晚期鳞状非小细胞肺癌具有极其显著疗效，优于紫杉醇化疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=de7a4538e16)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278921, encodeId=680b12e892174, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=市场能容纳多少PD-1抑制剂？, objectType=article, longId=44609, objectId=6b384460923, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6b384460923, replyNumber=0, likeNumber=78, createdTime=2014-12-27, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6b384460923, moduleTitle=市场能容纳多少PD-1抑制剂？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6b384460923)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278920, encodeId=daaa12e89201a, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价, objectType=article, longId=44538, objectId=2d0144538df, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2d0144538df, replyNumber=0, likeNumber=87, createdTime=2014-12-26, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2d0144538df, moduleTitle=FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2d0144538df)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278919, encodeId=038f12e891995, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期, objectType=article, longId=42706, objectId=31cd42e06ce, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=31cd42e06ce, replyNumber=0, likeNumber=79, createdTime=2014-11-19, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=31cd42e06ce, moduleTitle=回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=31cd42e06ce)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1278918, encodeId=66a412e8918e6, content=<a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=时美PD-1抑制剂Opdivo欧美监管收获好消息, objectType=article, longId=40989, objectId=76fb40989e4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=76fb40989e4, replyNumber=0, likeNumber=73, createdTime=2014-10-10, rootId=0, userName=xiongliangxl, userId=84fb152, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=76fb40989e4, moduleTitle=时美PD-1抑制剂Opdivo欧美监管收获好消息, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=76fb40989e4)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

PD-1抑制剂

2020-05-29

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

JAMA Oncol：不同肿瘤和治疗方案下，PD-1抑制剂相关肺炎发生情况如何？

2016-09-15

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

PD-1抑制剂Opdivo+Yervoy组合疗法黑色素瘤临床试验效果显著，1/3患者达到5年生存

2016-04-28

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

FDA接受施贵宝PD-1抑制剂Opdivo治疗肺癌上市申请，免疫疗法进入主流实体瘤

2015-03-04

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

Nivolumab三期临床提前终止，PD-1抑制剂治疗肺癌倒计时

2015-01-16

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

PD-1抑制剂对晚期鳞状非小细胞肺癌具有极其显著疗效，优于紫杉醇化疗

2015-01-14

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

市场能容纳多少PD-1抑制剂？

2014-12-27

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

FDA提前三个月批准施贵宝PD-1抑制剂Nivolumab(Opdivo)，与Keytruda同价

2014-12-26

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

回眸一笑百媚生：PD-1抑制剂nivolumab延长黑色素瘤患者生存期

2014-11-19

xiongliangxl (审核中...)

前往app查看评论内容

#PD-1抑制剂#

时美PD-1抑制剂Opdivo欧美监管收获好消息

2014-10-10

科室
- - 订阅+
  - 更多科室
工具
服务